BOOK NOW TO SAVE UP TO $600

April 24-26, 2018 | Boston, USA

www.as-immunetolerance.com

Antigen-Specific Immune Tolerance Drug Development

Accelerate the Discovery, Translational Success, Clinical Development and Commercialization of Safe and Effective Antigen-Specific Immune Tolerance Therapies

Expert Speakers Including:

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA



Lachy McLean
VP, Head of Clinical & Translational Sciences, Immunology
Takeda Pharmaceuticals

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

Jose M. Carballido
Executive Director & Translational Research Fellow
Novartis

Jack A. Ragheb
Senior Medical Fellow for Immunology
Eli Lilly & Co

Lawrence Steinman
Professor at Stanford University & Executive Chairman of the Board
Tolerion

Laurence A. Turka
CSO of Rheos Medicines; Deputy Director
Immune Tolerance Network

Matthias von Herrath
Professor at the La Jolla Institute for Allergy and Immunology; VP & Head of Type 1 Diabetes R&D Center Seattle
Novo Nordisk

Kei Kishimoto
CSO
Selecta Biosciences Inc.

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com

hansonwade

1st Antigen-Specific Immune Tolerance Drug Development Summit 2018

Successfully Overcome the Scientific, Product Development and Commercialization Challenges Associated with Developing Safe and Effective Antigen-Specific Immune Tolerance Therapies for Autoimmune Disorders.

As the first generation of antigen-specific immune tolerance therapies enter the clinic and excitement around recent partnerships, IPOs and investments reaches new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to unite.

Tackling key R&D challenges, such as antigen identification, animal modeling predictability, translation and clinical design along side future commercialization and regulatory challenges, this meeting is the first and only dedicated platform that brings key decision makers together to drive the future of these novel therapies. With excitement and opportunity for those who act now and successfully identify robust predictive models and translate basic immune tolerance research into effective therapies, join the 1st Antigen-Specific Immune Tolerance Drug Development Summit 2018 to rapidly translate the hype into reality.

Why we the speakers are looking forward to the summit?

"I am looking for the summit to inform me of what is happening in the field of translational tolerance and to inform colleagues of our approach to tolerance induction which is now in the clinic. It is finally time to test immune tolerance therapies in well designed and controlled clinical trials."
Stephen Miller- Cour Pharmaceutical

"I can participate in an exchange of ideas that will surely move the field towards the development of novel and efficacious therapies for immune-mediated diseases."
Francisco J. Quintana- AnTolRx

Why Attend the 1st Antigen-Specific Immune Tolerance Drug Development Summit 2018?

1. Revisit and widen your understanding of underlying causes of autoimmunity from world-class experts such as Immune Tolerance Network, NIH and Harvard University

2. Find out about the most innovative therapeutic approaches that target immune tolerance pathways from leading companies such as Takeda, Pfizer, Novartis & Eli Lilly

3. Through real world case studies from the likes of FDA, Tolerion, Nektar Therapeutics, AnTolRx, Selecta Biosciences & Topas Therapeutics maximize your success rates to translate ground breaking science into a novel class of therapies to treat autoimmunity



4. Debate, challenge and cut through the hurdles associated with successful translation from pre-clinic to clinic and how to design robust human trials for effective antigen-specific immune tolerance therapies



5. Find out what is the future regulatory and commercialization directions of antigen-specific immune tolerance therapies from the key decision makers within FDA, big pharma and leading biotech companies

Tel: +1 617 455 4188 Mail: info@hansonwade.com
www.as-immunetolerance.com

Your Expert Speakers

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Lachy McLean
VP, Head of Clinical & Translational Sciences, Immunology
Takeda Pharmaceuticals

Jose M. Carballido
Executive Director & Translational Research Fellow
Novartis

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

Jack A. Ragheb
Senior Medical Fellow for Immunology
Eli Lilly & Co

Lawrence Steinman
Professor at Stanford University & Executive Chairman of the Board
Tolerion

Laurence A. Turka
CSO of Rheos Medicines & Deputy Director
Immune Tolerance Network

Matthias von Herrath
Professor at the La Jolla Institute for Allergy and Immunology; VP & Head of Type 1 Diabetes R&D Center Seattle
Novo Nordisk

Julia Greenstein
VP, Research Strategy
JDRF

David W. Scott
Professor of Medicine & Vice Chair for Research
USUHS

Kei Kishimoto
CSO
Selecta Biosciences Inc.

Daniel Rotrosen
Director, Division of Allergy, Immunology & Transplantation
NIAID/NIH

Timm H. Jessen
CEO
Topas Therapeutics

Francisco J. Quintana
Associate Professor at Harvard; Co Founder & Director
AnTolRx

Jonathan Zalevsky
SVP Research & CSO
Nektar Therapeutics

Wojciech Jankowski
Research Reviewer, Center for Biologics Evaluation & Research
CBER/FDA

Todd Zion
President & CEO
Akston Biosciences

Stephan Kontos
Co-Founder & VP Research
Anokion and Kanyos Bio

Stephen Miller
Professor at Northwestern University Medical School & Co-founder
Cour Pharmaceutical

Clare M. Baecher-Allan
Assistant Professor of Neurology
Harvard University

Wanjun Chen
Senior Investigator (prof.) and Chief
NIDCR/NIH

Finola Moore
Project Leader & Senior Scientist
SQZ Biotech

Maximilian F. Konig
Resident Physician, Department of Medicine, Massachusetts General Hospital; Clinical Fellow in Medicine
Harvard Medical School

Why Are Our Expert Speakers Getting Involved at the Summit?

"It gives me the opportunity to network with peer companies, biotechs and academics who are active in this field to learn, build potential partnerships and share with others, how Pfizer accesses innovation through discovery and development."

Arpita Maiti - Pfizer

"This summit will help to explain different immunogenicity risk factors that complicate the drug development, but also will address solutions through the use of predictive assays, and tolerance induction strategies."

Wojciech Jankowski - CBER/FDA

"To learn new science and reach some consensus and collaborations hopefully."

Matthias von Herrath- Novo Nordisk

"The talks/discussions will indicate the level of interest by the bio-pharma industry in developing novel therapies and utilizing data that has been generated in academic labs."

Clare M. Baecher-Allan- Harvard University

"Sharing experiences in this important and growing aspect of how to treat patients with autoimmunity."

Laurence A. Turka - Immune Tolerance Network

"Participation will be valuable for exchange of information and if it promotes industry/non-profit/government collaborations."

Daniel Rotrosen - NIAID/NIH

"JDRF is committed to catalysing opportunities to make antigen specific approaches to prevention and treatment of T1D pushed to translation and being involved in this meeting will allow us to understand the opportunities and the gaps in the current efforts."

Julia Greenstein- JDRF

Conference Day One | Wednesday, 25 April, 2018

8.00 Registration & Breakfast

8.30 Chair's Opening Remarks

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome- Worldwide Research & Development
Pfizer

Dynamics of Underlying Causes & Current Understandings of Autoimmunity

Lawrence Steinman
Professor of Pediatrics and Neurology, Stanford University & Executive Chairman of the Board
Tolerion

8.40 The Underlying Causes of Autoimmunity: How to Develop Broader Immune Modulation Models?
- How to leverage our current understanding of causes of autoimmune diseases
- Explore emerging science & technologies towards overcoming autoimmunity

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome- Worldwide Research & Development
Pfizer

9.05 Accessing Innovation in Antigen-Specific Immune Tolerance – A Big Pharma View
- Antigen-specific immune tolerance will form the basis of future transformative therapies for autoimmune diseases that have the potential to be curative
- Approaches/modalities to induce immune tolerance are complex and will require innovation across the drug development and commercialization pathway
- Big pharma deploys multiple vehicles to access this innovation and augmenting it with in-house capabilities to bring new medicines to patients in need

Daniel Rotrosen
Director, Division of Allergy, Immunology, & Transplantation
NIAID/NIH

9.30 Overview of NIAID- Sponsored Research on Antigen-Specific Immune Tolerance
- Successful tolerance induction will require multifaceted approaches tailored to specific diseases and patient populations
- Partnerships spanning the pharmaceutical industry, non-profits, and governmental entities will be important in achieving this goal

Laurence A. Turka
CSO of Rheos Medicines & Deputy Director
Immune Tolerance Network

9.55 Tolerance in Type 1 Diabetes: The ITN Experience
- Novel approaches for tolerance in Type 1 Diabetes
- New mechanistic assays to monitor patients
- Insights from the above

10.20 Speed Networking & Morning Refreshments

Analyzing the Scope & Strategies to Antigen-Specific Immune Tolerance

Jose M. Carballido
Executive Director of Institutes Biomedical Research
Novartis

11.20 Challenges and Opportunities to Develop Immune Tolerance Approaches to Cure Type 1 Diabetes
- Immune tolerance has game changing potential for Type 1 Diabetes
- Exploratory biomarkers and digital health could accelerate clinical development in Type 1 Diabetes
- Combinations of immune tolerance and regenerative approaches might be required to treat entire patient population (e.g. also cases of long lasting disease)

Julia Greenstein
VP of Research Strategy
JDRF

11.45 The Potential of Antigen-Specific Therapies as Part of a Combination Approach to Type 1 Diabetes Therapy
- Type 1 Diabetes is both a beta cell and immune driven disease
- Combination therapies will be required to achieve significant therapeutic benefit
- Role of disease specific foundations in driving progress

Jack A. Ragheb
Senior Medical Fellow for Immunology
Eli Lilly & Co

12.10 The Potential of B Cell Tolerance in Autoimmunity
- Distinctions between B and T cell Tolerance
- Potential for Establishing Tolerance
- Do we need B cell Tolerance?

12.35 Networking Lunch

Identification, Validation & Targeting of Specific Antigens for Immune Tolerance Therapies

Clare M. Baecher-Allan
Assistant Professor of Neurology
Harvard University

13.45 Case Study: Key Lessons Learned from Regulatory T Cells for Cellular Therapy
- Human Tregs are comprised of functionally distinct subsets
- Lack of suppression can be due to Treg resistance
- Xenogeneic GVHD to examine human Treg cellular therapies

Maximilian F. Konig
Resident Physician, Department of Medicine, Massachusetts General Hospital; Clinical Fellow in Medicine
Harvard Medical School

14.10 Case Study: Etiologic Factors and Autoantigenic Targets in Rheumatoid Arthritis
- Rheumatoid arthritis (RA) is characterized by the presence of discrete autoantibody systems that target both native and posttranslationally modified proteins (citrullination, carbamylation, among others)
- Immune-mediated and microbial pore-forming pathways are potent drivers of abnormal protein citrullination in RA
- Understanding autoantigen selection and fine specificities may be critical for developing successful antigen-specific treatment strategies in RA

Finola Moore
Project Leader & Senior Scientist
SQZ Biotech

14.35 Case Study: Efficient Intracellular Microfluidic Delivery into RBCs to Induce Tolerance
- SQZ delivers antigen efficiently into RBCs
- SQZ's RBCs are cleared from circulation in a tolerogenic manner
- SQZ's RBCs prevent CD4 and CD8 response to model antigen Ova as well as disease models

15.00 Afternoon Refreshments & Networking

Improving the Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

Timm H. Jessen
CEO
Topas Therapeutics

15.30 Case Study: Generation of Antigen-Specific Immune Tolerance by Harnessing the Liver's Natural Capabilities
- The liver as a tolerogenic organ
- Accessing selected liver functionalities by nanoparticles
- Development requirements for nanomedicine

Stephen Miller
Professor of Microbiology-Immunology, Northwestern University Medical School; Co-Founder
Cour Pharmaceutical Dev. Company

15.55 Case Study: From Bench to Bedside: An Antigen-Encapsulating Nanoparticle-based Negative T Cell Vaccine for Tolerogenic Therapy of Autoimmune Disease

- Tolerance induction using antigen-encapsulating PLG nanoparticles recapitulates how self tolerance is maintained in the hematopoietic system
- Tolerance is exquisitely antigen-specific and depends on targeting tolerogenic APCs in the spleen and liver
- Tolerance induction and long-term maintenance is dependent on antigen-specific Tregs

Jonathan Zalevsky
SVP Research and CSO
Nektar Therapeutics

16.20 Case Study: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases

- Regulatory T cells numbers and suppressive function are elevated following administration of NKTR-358
- NKTR-358 is selective for regulatory T cells with a wide margin of activity between regulatory vs conventional T cells
- NKTR-358 delivers efficacy in multiple preclinical models, generating long-lasting antigen-specific regulatory T cell responses

Wanjun Chen
Senior Investigator (prof.) and Chief
NIDCR/NIH

16.45 Case Study: Induction of Autoantigen-Specific Regulatory T Cells *In Vivo* to Treat Autoimmunity

- How to induce autoantigen-specific regulatory T cells in the animals without compromising the overall immunity especially the anti-infection and anti-tumor immunity?
- Will show our success in animal models of autoimmunity, and hopefully to seek possibility and collaborations to translate these findings to human patients to do real precision medicine with purpose to treat/cure autoimmune diseases"

17.10 Panel Discussion: Pre-Clinical Proof of Concept *In Vivo*: Realistic or a Dream?

- What experimental models are available to test tolerogenic approaches?
- Which readouts can be used to predict efficacy in human studies?
- Can pre-clinical models identify readouts for proof of mechanism studies?

Moderator

Finola Moore
Project Leader & Senior Scientist
SQZ Biotech

Faculty

Todd Zion
President, CEO & Chairman
Akston Biosciences

Francisco J. Quintana
Associate Professor of Neurology, Harvard Medical School; Scientific Founder, Member Board of Directors
AnTolRx

Lachy McLean
VP, Head of Clinical & Translational Sciences, Immunology
Takeda Pharmaceuticals

18.00 Chair's Closing Remarks & End of Day One

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome- Worldwide Research & Development
Pfizer

Conference Day Two | Thursday, 26 April, 2018

8.00 Breakfast & Networking

9.00 Chair's Opening Remarks

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Surging Translational Potentials of Pre-Clinical Antigen-Specific Therapies

Matthias von Herrath
Professor at the La Jolla Institute for Allergy and Immunology; VP & Head of Type 1 Diabetes R&D Center Seattle
Novo Nordisk

9.10 Pathology of Human Type 1 Diabetes and New Antigenic Interventions

- Type 1 Diabetes might be relapsing remitting in some patients, therefore continuous treatment like an antigenic tolerance regimen might be needed
- We have found many published antigenic interventions in mouse models not to be robust enough
- Continuous treatment with antigen and suitable response modifiers might be needed for establishing beta cell specific tolerance. Combination treatments might also be needed

Wojciech Jankowski
Research Reviewer, Center for Biologics Evaluation & Research
CBER/FDA

9.35 Case Study: Non-Clinical Assessments of Immunogenicity

- The importance of immunogenicity during drug development and overview of regulatory Guidance Documents and White Papers that are available
- Two important concepts in immunogenicity risk assessment (with examples): (i) The ability to distinguish between validating a specific method and predicting clinical immunogenicity. (ii) Estimating the probability of anti-drug development vs. the consequences if such antibodies are generated
- Engineered protein therapeutics have neo-sequences introduced into them. How can one assess whether these may be neo-epitopes? If so, how does one mitigate the risk prior to starting clinical trials?

Francisco J. Quintana
Associate Professor of Neurology, Harvard Medical School; Scientific Founder & Member Board of Directors
AnTolRx

10.00 Case Study: Nanoparticles for the Induction of Antigen-Specific Tolerance

- Mechanisms that control tolerogenic DCs
- Nanoparticles for the induction of tolerance
- Translational potential

Todd Zion
President, CEO & Chairman
Akston Biosciences

10.25 Case Study: Targeting Insulin-Specific B Cells To Prevent Type 1 Diabetes

- Akston has developed a novel, modified insulin capable of deleting high affinity insulin-specific B cells and disrupting insulin-specific antigen presentation, while leaving the rest of the B cell repertoire untouched
- The lead candidate, AKS-107, prevents the development of Type 1 Diabetes in non-obese diabetic (NOD) mice with lasting effects after cessation of dosing. AKS-107-treated NOD mice confer disease protection after adoptive lymphocyte transfer
- Studies in non-human primates demonstrate the safety of AKS-107 and its long serum half-life supporting q2w dosing. The compound is now being developed under good manufacturing practice (GMP) to support first-in-human clinical trials

Stephan Kontos
Co-Founder, VP of Research
Anokion & Kanyos Bio

10.50 Case Study: Harnessing Natural Tolerance Pathways with Targeted Delivery Technologies Induces Robust Antigen-Specific Tolerance

- Mimicking physiological tolerance mechanisms by way of active targeting domains induces antigen-specific T cell tolerance
- Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs (T cell deletion and regulation), and our molecules are developable
- Discuss potential approaches to de-risk MoA's in higher-order species, and consider their value

11.15 Morning Refreshments & Networking

Optimizing Clinical Development & Paving the Future of Antigen-Specific Immune Tolerance Therapies

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

11.45 Immune Tolerance Induction: Clinical Urgency as a Factor in Dictating Approach

- Rapid induction of tolerance may require non-antigen specific approaches
- Prophylactic tolerance induction requires less duration and intensity of immune suppression
- Rapid induction of antigen-specific immune tolerance requires consideration of combination therapies

Kei Kishimoto
CSO
Selecta Biosciences

12.10 Case Study: Pre-clinical & Clinical Development of Tolerogenic Nanoparticles to Mitigate Immunogenicity Against Biologic Drugs

- We have developed biodegradable Synthetic Vaccine Particles containing rapamycin (SVP-Rapamycin) that induce tolerogenic dendritic cells and antigen-specific regulatory T cells
- SVP-Rapamycin has been shown to mitigate immunogenicity against a wide variety of biologic drugs, including adalimumab in a model of inflammatory arthritis, coagulation Factor VIII in haemophilia A mice, acid alpha glucosidase in a model of Pompe Disease, immunotoxin in a model of mesothelioma, pegylated uricase in uricase deficient mice, and AAV gene therapy vectors
- SVP-Rapamycin is currently in Phase 2 clinical trials with pegsiticase, a pegylated uricase enzyme, in patients with symptomatic gout and hyperuricemia

Lawrence Steinman
Professor of Pediatrics and Neurology, Stanford University & Executive Chairman of the Board
Tolerion

12.35 Case Study: Antigen- Specific Tolerance for Type 1 Diabetes, Neuromyelitis Optica, Myasthenia Gravis and Protein Replacement Therapy

- Clinical Efficacy in Phase 2a trial of type 1 diabetes when tolerizing to proinsulin in type 1 diabetes
- Promising pre-clinical results in neuromyelitis optica, myasthenia gravis
- Promising pre-clinical results in gene therapy of Duchenne Muscular Dystrophy

13.00 Networking Lunch

Commercialization: Future Proofing Immune Tolerance Therapies for Patients

14.00 Panel Discussion: How to Develop Transferable and Durable Antigen-Specific Immune Tolerance Therapies?

- How to deal with the complex human immune system?
- How to select precise subpopulations and build expandability to entire disease target?
- How to ensure safety and efficacy?

Moderator

Julia Greenstein
VP of Research Strategy
JDRF

Faculty

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Jose M. Carballido
Executive Director of Institutes Biomedical Research
Novartis

Timm H. Jessen
CEO
Topas Therapeutics

14.45 Panel Discussion: How to Develop Commercially Viable Antigen-Specific Immune Tolerance Therapies?

- What learnings can be leveraged from other non-traditional modalities to develop antigen-specific tolerogenic therapies?
- How to anticipate chemistry, manufacturing, and controls (CMC) hurdles?
- What are some of the advantages of the these therapies in the context of manufacturing?

Moderator

Daniel Rotrosen
Director, Division of Allergy, Immunology, & Transplantation
NIAID/NIH

Faculty

Lachy McLean
VP, Head of Clinical & Translational Sciences, Immunology
Takeda Pharmaceuticals

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome- Worldwide Research & Development
Pfizer

Matthias von Herrath
Professor at the La Jolla Institute for Allergy and Immunology; VP & Head of Type 1 Diabetes R&D Center Seattle
Novo Nordisk

15.30 Chair's Closing Remarks & End of the Summit, Followed by Afternoon Refreshments & Networking

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

"I look forward to learning more about the various interesting antigen-specific tolerance approaches being pursued clinically and pre-clinically, and discussing with key leaders in the field on topics related to translational biomarkers, CMC, and animal modelling."
Stephan Kontos- Anokion & Kanyos Bio

Pre-Conference Workshop Day | Tuesday, 24 April, 2018

Workshop A

Translation from Animal to Human Studies: A Workshop on Strategies & Applications

09:00am – 12:00pm

This interactive workshop session will delve deep into the challenges associated with the lack of predictability and robustness of pre-clinical models. Join this session to increase your rate of success in clinical development by overcoming the translational, regulatory, and financial hurdles to safely and effectively take these first in class resolution antigen-specific immune tolerance therapies from bench to bedside.

A workshop on strategies & applications

- In which species does a novel therapy need to be tested?
- What are the technical research issues?
- Which disease targets are "low hanging fruit"?
- What are the regulatory hurdles?
- What are the Financial hurdles?

Workshop Leader

David W. Scott, Professor of Medicine & Vice Chair for Research, **USUHS**

Professor David W. Scott, Ph.D. is Vice Chair for Research in the Department of Medicine at the Uniformed Services School of Health Sciences, Bethesda, MD, since 2010. An alumnus of Antioch, University of Chicago and Yale, and a post-doc at Oxford, he held tenured faculty positions at Duke, University of Rochester, and the U. Maryland Medical School. Dr. Scott has contributed to over 200 research papers on several subjects on immunologic tolerance, and its application in hemophilia. The author of two textbooks and recipient of a number of awards from the AAI, a Boerhaave Professorship at Leiden University and a Scientific Achievement Award from AAPS.

Workshop B

How to Induce Antigen-Specific Immune Tolerance Through Nanoparticles as a Platform?

13:00pm – 16:00pm

Tolerogenic nanoparticles are rapidly being developed as specific immunotherapies to treat autoimmunity. However, as with any emerging approach, there are many uncertainty associated with the safety, efficacy and design and administration process of nanoparticles. This workshop highlights the challenges and opportunities of a nanoparticle approach to immune tolerance induction by addressing the fundamentals in-depth.

- How to best define the spectrum of self antigens driving a particular autoimmune disease to be targeted for tolerance induction?
- What preclinical models are necessary to test before first-in-man clinical trials?
- What are the optimal disease indications for first assessing successful tolerance induction in man?
- How to best determine the nanoparticle composition and route of administration for developing a robust tolerance therapy?
- How to best design a clinical trial to assess the mechanisms underlying tolerance induction and maintenance in man?

Workshop Leader

Stephen Miller, Professor at Northwestern University Medical School & Co-founder, **Cour Pharmaceutical Dev. Company**

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago and he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center. Dr. Miller's work has significantly enhanced understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). His current work is geared to translating the use of antigen-linked biodegradable PLG nanoparticles for the treatment of human immune-mediated diseases including autoimmunity, allergy and tissue/organ transplantation.

SPONSORSHIP OPPORTUNITIES

WHY PARTNER WITH US?

Benefit from Market Intelligence

There is a severe unmet medical need as it currently stands to battle autoimmunity. Hear how and where pharmaceutical giants are looking to close this gap to match your solutions accordingly.

Raise Brand Awareness

Benefit from pre and post conference exposure to our autoimmunity community and increase market share through unique branding formats. Also, differentiate to help biopharma accelerate their immune tolerance drug development services from other solution providers.

Position Yourself as an Industry Expert

With the emergence of first generation of clinical data, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent clinical expertise in front of the key decision makers in the field.

Meet and Network with Industry Pioneers

With a room full of drug developers looking to see how they can effectively apply targeted immune tolerance solutions to increase clinical success, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.

Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

TYPES OF COMPANIES ATTENDING*



*Based on market research and previous events' statistics

WHO WILL YOU MEET?

- **60+** Attendees
- **6+** Hours of Dedicated Networking
- **2** Interactive Workshops
- **12+** Real World Case Studies

SENIORITY



*Based on market research and previous events' statistics

BECOME A PARTNER

James Woodcock
Commercial Directors
Antigen-Specific Immune Tolerance Event Series
T: +44 (0) 20 3141 8739
E: james.woodcock@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

Tel: +1 617 455 4188

Email: register@hansonwade.com

Web: as-immunetolerance.com

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

1. Find out about the most innovative therapeutic approaches that target immune tolerance pathways.
2. Debate, challenge and cut through the hurdles associated with successful translation from pre-clinic to clinic and how to design robust human trials for effective antigen-specific immune tolerance therapies.
3. Find out what is the future regulatory and commercialization direction of antigen-specific immune tolerance therapies from the key decision makers within FDA, big pharma and leading biotech companies.

SECURE YOUR PLACE

Drug Developers (Pharma & Biotech)	Register & Pay before Friday 26 January **Save up to $600**	Standard Prices
Conference + 2 Workshops	$3,197	$3,797
Conference + 1 Workshop	$2,798	$3,398
Conference Only	$2,199	$2,799
Workshop Only	$599	
2 Workshops	$998 **(SAVE $200)**	

Academics	Register & Pay before Friday 26 January **Save up to $400**	Standard Prices
Conference + 2 Workshops	$2,357	$2,757
Conference + 1 Workshop	$2,058	$2,458
Conference Only	$1,559	$1,959
Workshop Only	$499	
2 Workshops	$798 **(SAVE $200)**	

VENUE

The Aloft Boston Seaport
401-403 D Street Boston
Massachusetts 02210
United States

For further information or assistance, please visit www.starwoodhotels.com/alofthotels/property/overview/index.html?propertyID=4142

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149